FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280575950> ?p ?o ?g. }

• W4280575950 endingPage "3241" @default.
• W4280575950 startingPage "3235" @default.
• W4280575950 abstract "The PI3K pathway is dysregulated in the majority of triple-negative breast cancers (TNBC), yet single-agent inhibition of PI3K has been ineffective in TNBC. PI3K inhibition leads to an immediate compensatory upregulation of the Wnt pathway. Dual targeting of both pathways is highly synergistic against TNBC models in vitro and in vivo. We initiated a phase I clinical trial combining gedatolisib, a pan-class I isoform PI3K/mTOR inhibitor, and cofetuzumab pelidotin, an antibody-drug conjugate against the cell-surface PTK7 protein (Wnt pathway coreceptor) with an auristatin payload.Participants (pt) had metastatic TNBC or estrogen receptor (ER) low (ER and PgR < 5%, HER2-negative) breast cancer, and had received at least one prior chemotherapy for advanced disease. The primary objective was safety. Secondary endpoints included overall response rate (ORR), clinical benefit at 18 weeks (CB18), progression-free survival (PFS), and correlative analyses.A total of 18 pts were enrolled in three dose cohorts: gedatolisib 110 mg weekly + cofetuzumab pelidotin 1.4 mg/kg every 3 weeks (n = 4), 180 mg + 1.4 mg/kg (n = 3), and 180 mg + 2.8 mg/kg (n = 11). Nausea, anorexia, fatigue, and mucositis were common but rarely reached ≥grade 3 severity. Myelosuppression was uncommon. ORR was 16.7% (3/18). An additional 3 pts had stable disease (of these 2 had stable disease for >18 weeks); CB18 was 27.8%. Median PFS was 2.0 months (95% confidence interval for PFS: 1.2-6.2). Pts with clinical benefit were enriched with genomic alterations in the PI3K and PTK7 pathways.The combination of gedatolisib + cofetuzumab pelidotin was well tolerated and demonstrated promising clinical activity. Further investigation of this drug combination in metastatic TNBC is warranted." @default.
• W4280575950 created "2022-05-22" @default.
• W4280575950 creator A5006346528 @default.
• W4280575950 creator A5009816526 @default.
• W4280575950 creator A5049097819 @default.
• W4280575950 creator A5049263574 @default.
• W4280575950 creator A5053390874 @default.
• W4280575950 creator A5064024878 @default.
• W4280575950 creator A5064891388 @default.
• W4280575950 creator A5066378604 @default.
• W4280575950 creator A5068666503 @default.
• W4280575950 creator A5076252332 @default.
• W4280575950 creator A5080410100 @default.
• W4280575950 date "2022-05-12" @default.
• W4280575950 modified "2023-10-01" @default.
• W4280575950 title "Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer" @default.
• W4280575950 cites W1919257374 @default.
• W4280575950 cites W1928167867 @default.
• W4280575950 cites W1969346276 @default.
• W4280575950 cites W1973071608 @default.
• W4280575950 cites W1973537879 @default.
• W4280575950 cites W1997640760 @default.
• W4280575950 cites W2028862921 @default.
• W4280575950 cites W2044702943 @default.
• W4280575950 cites W2082004605 @default.
• W4280575950 cites W2096283457 @default.
• W4280575950 cites W2098408143 @default.
• W4280575950 cites W2103441770 @default.
• W4280575950 cites W2106660927 @default.
• W4280575950 cites W2109404953 @default.
• W4280575950 cites W2110017381 @default.
• W4280575950 cites W2118605519 @default.
• W4280575950 cites W2135967835 @default.
• W4280575950 cites W2147960762 @default.
• W4280575950 cites W2170602872 @default.
• W4280575950 cites W2170856503 @default.
• W4280575950 cites W2171972386 @default.
• W4280575950 cites W2342880723 @default.
• W4280575950 cites W2560367415 @default.
• W4280575950 cites W2574836938 @default.
• W4280575950 cites W2606277010 @default.
• W4280575950 cites W2612467560 @default.
• W4280575950 cites W2882877722 @default.
• W4280575950 cites W2952165232 @default.
• W4280575950 cites W2964845832 @default.
• W4280575950 cites W3006930853 @default.
• W4280575950 cites W3086278271 @default.
• W4280575950 cites W3088810176 @default.
• W4280575950 cites W3093265161 @default.
• W4280575950 cites W3097171810 @default.
• W4280575950 cites W3109853980 @default.
• W4280575950 cites W4238492599 @default.
• W4280575950 doi "https://doi.org/10.1158/1078-0432.ccr-21-3078" @default.
• W4280575950 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35551360" @default.
• W4280575950 hasPublicationYear "2022" @default.
• W4280575950 type Work @default.
• W4280575950 citedByCount "5" @default.
• W4280575950 countsByYear W42805759502021 @default.
• W4280575950 countsByYear W42805759502022 @default.
• W4280575950 countsByYear W42805759502023 @default.
• W4280575950 crossrefType "journal-article" @default.
• W4280575950 hasAuthorship W4280575950A5006346528 @default.
• W4280575950 hasAuthorship W4280575950A5009816526 @default.
• W4280575950 hasAuthorship W4280575950A5049097819 @default.
• W4280575950 hasAuthorship W4280575950A5049263574 @default.
• W4280575950 hasAuthorship W4280575950A5053390874 @default.
• W4280575950 hasAuthorship W4280575950A5064024878 @default.
• W4280575950 hasAuthorship W4280575950A5064891388 @default.
• W4280575950 hasAuthorship W4280575950A5066378604 @default.
• W4280575950 hasAuthorship W4280575950A5068666503 @default.
• W4280575950 hasAuthorship W4280575950A5076252332 @default.
• W4280575950 hasAuthorship W4280575950A5080410100 @default.
• W4280575950 hasBestOaLocation W42805759501 @default.
• W4280575950 hasConcept C121608353 @default.
• W4280575950 hasConcept C126322002 @default.
• W4280575950 hasConcept C143998085 @default.
• W4280575950 hasConcept C203092338 @default.
• W4280575950 hasConcept C2775930923 @default.
• W4280575950 hasConcept C2776694085 @default.
• W4280575950 hasConcept C2778496288 @default.
• W4280575950 hasConcept C2779984678 @default.
• W4280575950 hasConcept C2780110267 @default.
• W4280575950 hasConcept C31760486 @default.
• W4280575950 hasConcept C530470458 @default.
• W4280575950 hasConcept C535046627 @default.
• W4280575950 hasConcept C71924100 @default.
• W4280575950 hasConceptScore W4280575950C121608353 @default.
• W4280575950 hasConceptScore W4280575950C126322002 @default.
• W4280575950 hasConceptScore W4280575950C143998085 @default.
• W4280575950 hasConceptScore W4280575950C203092338 @default.
• W4280575950 hasConceptScore W4280575950C2775930923 @default.
• W4280575950 hasConceptScore W4280575950C2776694085 @default.
• W4280575950 hasConceptScore W4280575950C2778496288 @default.
• W4280575950 hasConceptScore W4280575950C2779984678 @default.
• W4280575950 hasConceptScore W4280575950C2780110267 @default.
• W4280575950 hasConceptScore W4280575950C31760486 @default.
• W4280575950 hasConceptScore W4280575950C530470458 @default.
• W4280575950 hasConceptScore W4280575950C535046627 @default.

• next